Movement Alert｜WuXi XDC Rises 3.18% in Regular Trading, Subsidiary Secures WuXi Biologics Order Amid Sector Rally

Market Focus

Jun 18

On June 18, WuXi XDC (02268.HK) rose 3.18% in regular trading, trading at HKD 47.14/share, with turnover of HKD 81.26 million. The stock rebounded from recent lows following a key subsidiary development and broad sector strength.

On the news front, WuXi XDC's controlled subsidiary Topharman (01875.HK) signed a process development and manufacturing service agreement with WuXi Biologics on June 16. Under the agreement, Topharman will provide process development and manufacturing services for monoclonal antibody intermediates, delivering a total of 10 batches at RMB 1.9 million per batch, totaling RMB 19 million. The services cover cell recovery, cell passage, N-stage cell culture, protein purification, and excipient addition. All orders must be placed before December 31, with each batch delivered within 60-90 calendar days of order confirmation. The agreement is expected to deepen Topharman's technical know-how and enhance its process capabilities.

Additionally, the broader Life Sciences Tools and Services sector showed strong momentum, with WuXi Biologics up 3.95%, WuXi AppTec up 4.08%, and GenScript Biotech up 4.97%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1160058398"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1160058398\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1160058398?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-18 10:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160058398","market":"us","top_or_hot":-1,"title":"Movement Alert｜WuXi XDC Rises 3.18% in Regular Trading, Subsidiary Secures WuXi Biologics Order Amid Sector Rally","media":"Market Focus","content":"<p><p>On June 18, WuXi XDC (02268.HK) rose 3.18% in regular trading, trading at HKD 47.14/share, with turnover of HKD 81.26 million. The stock rebounded from recent lows following a key subsidiary development and broad sector strength.</p><p>On the news front, WuXi XDC's controlled subsidiary Topharman (01875.HK) signed a process development and manufacturing service agreement with WuXi Biologics on June 16. Under the agreement, Topharman will provide process development and manufacturing services for monoclonal antibody intermediates, delivering a total of 10 batches at RMB 1.9 million per batch, totaling RMB 19 million. The services cover cell recovery, cell passage, N-stage cell culture, protein purification, and excipient addition. All orders must be placed before December 31, with each batch delivered within 60-90 calendar days of order confirmation. The agreement is expected to deepen Topharman's technical know-how and enhance its process capabilities.</p><p>Additionally, the broader Life Sciences Tools and Services sector showed strong momentum, with WuXi Biologics up 3.95%, WuXi AppTec up 4.08%, and GenScript Biotech up 4.97%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜WuXi XDC Rises 3.18% in Regular Trading, Subsidiary Secures WuXi Biologics Order Amid Sector Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜WuXi XDC Rises 3.18% in Regular Trading, Subsidiary Secures WuXi Biologics Order Amid Sector Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-18 10:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 18, WuXi XDC (02268.HK) rose 3.18% in regular trading, trading at HKD 47.14/share, with turnover of HKD 81.26 million. The stock rebounded from recent lows following a key subsidiary development and broad sector strength.</p><p>On the news front, WuXi XDC's controlled subsidiary Topharman (01875.HK) signed a process development and manufacturing service agreement with WuXi Biologics on June 16. Under the agreement, Topharman will provide process development and manufacturing services for monoclonal antibody intermediates, delivering a total of 10 batches at RMB 1.9 million per batch, totaling RMB 19 million. The services cover cell recovery, cell passage, N-stage cell culture, protein purification, and excipient addition. All orders must be placed before December 31, with each batch delivered within 60-90 calendar days of order confirmation. The agreement is expected to deepen Topharman's technical know-how and enhance its process capabilities.</p><p>Additionally, the broader Life Sciences Tools and Services sector showed strong momentum, with WuXi Biologics up 3.95%, WuXi AppTec up 4.08%, and GenScript Biotech up 4.97%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02268","symbol_name":"药明合联","start_time":0,"source_url":"","article_id":"1160058398","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160058398","pubTimestamp":1781749732,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 18, WuXi XDC (02268.HK) rose 3.18% in regular trading, trading at HKD 47.14/share, with turnover of HKD 81.26 million. The stock rebounded from recent lows following a key subsidiary...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02268":"药明合联"},"translate_title":"异动提示|药明生物常规交易上涨3.18%子公司在板块反弹中获得药明生物订单","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02268":1},"content_text":"On June 18, WuXi XDC (02268.HK) rose 3.18% in regular trading, trading at HKD 47.14/share, with turnover of HKD 81.26 million. The stock rebounded from recent lows following a key subsidiary development and broad sector strength.On the news front, WuXi XDC's controlled subsidiary Topharman (01875.HK) signed a process development and manufacturing service agreement with WuXi Biologics on June 16. Under the agreement, Topharman will provide process development and manufacturing services for monoclonal antibody intermediates, delivering a total of 10 batches at RMB 1.9 million per batch, totaling RMB 19 million. The services cover cell recovery, cell passage, N-stage cell culture, protein purification, and excipient addition. All orders must be placed before December 31, with each batch delivered within 60-90 calendar days of order confirmation. The agreement is expected to deepen Topharman's technical know-how and enhance its process capabilities.Additionally, the broader Life Sciences Tools and Services sector showed strong momentum, with WuXi Biologics up 3.95%, WuXi AppTec up 4.08%, and GenScript Biotech up 4.97%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}